Results 1 to 10 of about 135,903 (137)
Applications of Pharmacometrics in Antibody–Drug Conjugate Development [PDF]
PharmaceuticsAntibody–drug conjugates (ADCs), which integrate a cytotoxic drug known as the payload into a tumor-targeting monoclonal antibody via a linker, have emerged as promising candidates for cancer therapy and are a new avenue for targeted cancer therapy.
Xiaoliang Cheng +3 more
doaj +2 more sources
Novel Immune Checkpoint Inhibitor and Antibody–Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer [PDF]
Current OncologyImmune checkpoint inhibitors and antibody drug conjugate combinations have revolutionized the management of patients with advanced and metastatic urothelial carcinoma, offering unprecedented survival outcomes. These treatments are now moving into earlier
Joseph Vento +4 more
doaj +2 more sources
CD74-Targeted Cathepsin-Inhibitor Antibody–Drug Conjugate Triggers Apoptosis in DLBCL [PDF]
CellsTranscriptomic analyses of public datasets (TCGA and GTEx) revealed that both CD74 and Cathepsin L (CTSL) are significantly overexpressed in diffuse large B-cell lymphoma (DLBCL) compared to normal tissues, and that their expression levels are highly ...
Ihab Abd-Elrahman +7 more
doaj +2 more sources
HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer [PDF]
Cancer MedicineBackground HER2‐targeted antibody‐drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2‐targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other ...
Seohyuk Lee +5 more
doaj +2 more sources
Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion [PDF]
American Journal of Ophthalmology Case ReportsPurpose: To report a case of bilateral corneal pseudomicrocysts associated with infusions of a novel antibody-drug conjugate targeting claudin-6, called TORL-1-23.
Laura Matuszewska +5 more
doaj +2 more sources
Pharmaceuticals, 2022 Although there have been extensive research and progress on the discovery of anticancer drug over the years, the application of these drugs as stand-alone therapy has been limited by their off-target toxicities, poor pharmacokinetic properties, and low ...
Audrey Nathania Johan, Yi Li
doaj +1 more source
Antibody–Drug Conjugate to Treat Meningiomas
Pharmaceuticals, 2021 Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control ...
Kai Chen +9 more
doaj +1 more source
Communications Medicine, 2021 Lee et al. use an antibody-drug conjugate to treat pathologic ocular neovascularization in mouse models. The antibody-drug conjugate targets PDGFRβ-expressing pericytes, with similar therapeutic effects to an anti-VEGF agent and with limited unwanted ...
Seok Jae Lee +10 more
doaj +1 more source
Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting
Frontiers in Immunology, 2023 Cancerous B cells are almost indistinguishable from their non-malignant counterparts regarding their surface antigen expression. Accordingly, the challenge to be faced consists in elimination of the malignant B cell population while maintaining a ...
Katrin Schoenfeld +5 more
doaj +1 more source
Antibody-Drug Conjugate-Induced Pneumonitis: A Growing Threat [PDF]
Journal of Immunotherapy and Precision OncologyKathy L. Chan +2 more
doaj +2 more sources